--- title: "3 Japanese Large Caps Trading Below Fair Value on Cash Flow Estimates" type: "News" locale: "en" url: "https://longbridge.com/en/news/291311239.md" description: "The article highlights three Japanese large-cap stocks—Round One, Chugai Pharmaceutical, and Taiyo Yuden—that appear undervalued based on discounted cash flow estimates. Round One offers high ROE but relies on debt; Chugai boasts strong margins via its Roche partnership despite patent risks; and Taiyo Yuden shows growth potential in electronic components despite modest current profitability. Investors are advised to weigh these cash flow valuations against specific operational and financial risks." datetime: "2026-06-30T15:58:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291311239.md) - [en](https://longbridge.com/en/news/291311239.md) - [zh-HK](https://longbridge.com/zh-HK/news/291311239.md) --- # 3 Japanese Large Caps Trading Below Fair Value on Cash Flow Estimates With inflation trends mixed across major economies and central banks still weighing their next moves, many investors are looking past short term headlines and focusing on one thing that is harder to fake: cash generation. The Undervalued Stocks Based On Cash Flows screener targets companies where discounted cash flow analysis suggests the share price does not fully reflect their cash flow potential, at a time when resilient demand in areas like services and high tech manufacturing is still supporting global activity. This article highlights 3 stocks from that screener that stand out on cash flow value today. ## Round One (TSE:4680) **Overview:** Round One (TSE:4680) runs large indoor leisure complexes across Japan and overseas, offering bowling, arcade games, karaoke, billiards and multi sport “Spo Cha” arenas under one roof. The company essentially sells families and young adults an all in one entertainment experience, monetising time spent across multiple activities during each visit. **Operations:** Round One generates most of its revenue in Japan at ¥108,689 million, with a significant contribution from the United States at ¥79,662 million and a small amount from other regions at ¥1,196 million. **Market Cap:** ¥309.5b ## Why Round One is catching value focused attention Round One appears on this cash flow screener because the estimated fair value sits meaningfully above the current share price, while the P/E of 18.4x is lower than both the JP Hospitality average and the estimated fair P/E of 25.2x. Earnings forecasts of around 13% a year and a high 20.1% ROE indicate a business that is turning its leisure footprint into profitability, with margins currently around 8.8%. The trade off is a funding structure that leans heavily on external borrowing, which can increase sensitivity to interest costs. Upcoming events such as the fiscal 2026 results and the scheduled dividend may provide catalysts that more detailed research on Round One could put into better context. Round One’s earnings forecasts around 13% a year and 20.1% ROE suggest cash generation that the current P/E may not fully capture, so it is worth studying the DCF valuation analysis for Round One to see what the market might be missing about its borrowing heavy model. 4680 Discounted Cash Flow as at Jun 2026 ## Chugai Pharmaceutical (TSE:4519) **Overview:** Chugai Pharmaceutical (TSE:4519) is a Japan based drug company focused on researching, developing, manufacturing and selling prescription medicines for cancer, autoimmune and other serious diseases, with a portfolio that includes oncology therapies like Herceptin and Tecentriq, as well as treatments for conditions such as rheumatoid arthritis, spinal muscular atrophy and influenza. **Operations:** Chugai Pharmaceutical generates all of its ¥1,291,229 million in revenue from pharmaceuticals, with reported sales concentrated in Japan and Switzerland. **Market Cap:** ¥12.5t ## Why Chugai Pharmaceutical stands out on cash flow value Chugai Pharmaceutical combines high margin biologic drugs and personalized medicine with a long standing partnership with Roche that gives it access to global R&D and distribution. This relationship helps explain its profit margin of around 35%. At the same time, the stock is described as being priced below some estimates of fair value based on future cash flows, and analysts cited in the article expect returns on equity in the mid 20% range. The catch is heavy dependence on a handful of flagship products and exposure to pricing pressure and patent expiries, so anyone drawn to its cash generation and drug pipeline needs to weigh those concentration and regulatory risks carefully. Chugai Pharmaceutical’s strong margins and Roche partnership could be masking a very different story on long term cash generation, so it is worth reading the 4 key rewards and 1 important warning sign TSE:4519 Earnings & Revenue Growth as at Jun 2026 ## Taiyo Yuden (TSE:6976) **Overview:** Taiyo Yuden (TSE:6976) is a Tokyo based electronics company that designs and manufactures key components like multilayer ceramic capacitors, inductors, RF and high frequency devices that sit inside smartphones, wearables, automotive systems and other electronic equipment worldwide. **Operations:** Taiyo Yuden generates all of its ¥355,341 million in revenue from its Electronic Components Business, with sales spread across China, Japan, Europe, Taiwan, Hong Kong, North America and other regions. **Market Cap:** ¥2.3t ## Why Taiyo Yuden is on cash flow investors’ radar Taiyo Yuden combines exposure to demand for electronic components with forecasts for faster earnings and revenue growth than the wider Japanese market, while its current share price is described as sitting below estimated future cash flow value. Profitability is still modest, with a 4.2% net margin and low current ROE, and the balance sheet leans entirely on external borrowing, which adds funding risk. Recent product launches for smartphones, wearables and automotive grade capacitors show how closely Taiyo Yuden is tied to key end markets, but a recent analyst downgrade and share price volatility highlight that not everyone is convinced. The missing piece is how these projects, governance questions and leverage interact when you look at the full picture of Taiyo Yuden’s cash generation potential. Taiyo Yuden’s earnings story and share price swings hint at a gap between perception and reality. The analysis report for Taiyo Yuden could reveal how its leverage and end market exposure really fit together. TSE:6976 Earnings & Revenue Growth as at Jun 2026 The three stocks covered here are just a starting point, with the full Undervalued Stocks Based On Cash Flows screen uncovering 49 more companies flagged by the Undervalued Stocks Based On Cash Flows screener for similarly compelling cash flow driven narratives. Use Simply Wall St to identify and analyze the specific catalysts, funding profiles and cash flow patterns that matter to you so you can focus on the opportunities you find most compelling. ## Take Control of Your Investment Journey If Chugai Pharmaceutical or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market. ## Seeking Fresh Alternatives Before They Fly? New ideas can move from under the radar to full momentum fast. The best entry points often appear briefly before the crowd catches on, so consider acting while they are still emerging. - Spot potential breakout income plays by scanning companies in the 55 dividend fortresses that pair higher yields with balance sheets designed to keep those payouts supported. - Chase early momentum in companies building the next wave of automation by reviewing the curated set of 29 robotics and automation stocks shaping factories, logistics and everyday devices. - Get ahead of power grid upgrades by tracking curated 35 power grid technology and infrastructure stocks that could benefit as electricity demand, transmission needs and grid tech requirements continue to evolve. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [6976.JP](https://longbridge.com/en/quote/6976.JP.md) - [4680.JP](https://longbridge.com/en/quote/4680.JP.md) - [4519.JP](https://longbridge.com/en/quote/4519.JP.md) - [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md) - [CHGCY.US](https://longbridge.com/en/quote/CHGCY.US.md) - [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md) ## Related News & Research - [Chugai seeks Japan approval for Enspryng to prevent MOGAD relapses](https://longbridge.com/en/news/294463834.md) - [Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand](https://longbridge.com/en/news/294353303.md) - [Large-cap Sell streak: 10 stocks trapped longest in bearish Quant ratings](https://longbridge.com/en/news/294953562.md) - [$1000 Invested In Vanguard Morningstar Mega Cap Growth ETF 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/294711672.md) - [IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update | IDYA Stock News](https://longbridge.com/en/news/294802748.md)